Emtricitabine News and Research

RSS
Emtricitabine, also known as Emtriva or FTC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Emtricitabine in capsule form was approved by the FDA on July 2, 2003, for use with other antiretroviral agents in the treatment of HIV infection in adults. Emtricitabine oral solution was approved by the FDA on September 28, 2005, and is now approved for use with other anti-HIV drugs in the treatment of HIV-1 infection in patients older than 3 months of age. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Researchers launch phase II clinical trial of rectal microbicide to prevent HIV infections

Researchers launch phase II clinical trial of rectal microbicide to prevent HIV infections

More AIDS-defining illnesses and severe side effects occur with appropriate comparator therapy

More AIDS-defining illnesses and severe side effects occur with appropriate comparator therapy

FDA: New drug Tivicay approved to treat HIV-1 infection

FDA: New drug Tivicay approved to treat HIV-1 infection

New WHO guidelines recommend earlier treatment for people living with HIV

New WHO guidelines recommend earlier treatment for people living with HIV

Drug Innovation Ventures provides development and commercialization solutions for traditional academic drug discovery

Drug Innovation Ventures provides development and commercialization solutions for traditional academic drug discovery

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

Indonesia to issue compulsory licenses for HIV, hepatitis B drugs still under patent

Indonesia to issue compulsory licenses for HIV, hepatitis B drugs still under patent

Study finds antiretroviral-based strategies to prevent HIV infection among women prove ineffective

Study finds antiretroviral-based strategies to prevent HIV infection among women prove ineffective

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead commences first of two tenofovir alafenamide Phase 3 trials in HIV

Gilead commences first of two tenofovir alafenamide Phase 3 trials in HIV

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen announces U.S. prescribing information update for EDURANT tablets

IQWiG investigates benefits of rilpivirine for HIV treatment

IQWiG investigates benefits of rilpivirine for HIV treatment

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Study estimates drug concentrations of Truvada and tenofovir to reduce risk of HIV among MSM

Study estimates drug concentrations of Truvada and tenofovir to reduce risk of HIV among MSM

FDA approves Gilead’s Stribild to treat HIV-1 infection

FDA approves Gilead’s Stribild to treat HIV-1 infection

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences signs deals with 3 Indian pharmaceutical companies to promote low-cost HIV drugs in developing countries

Gilead Sciences signs deals with 3 Indian pharmaceutical companies to promote low-cost HIV drugs in developing countries